Articles On Cardiex (ASX:CDX)

RBA lifts rates 25 basis points, says there’s more where that came from ASX immediately sags 0.5% on news from the Reserve Bank Federal Court finds in favour of Nuix over former CEO’s $183 million claim   The ASX has had a choppy old day,...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX puts on a late spurt to finish the day up 0.5% Star Entertainment and Bluescope in very hot water  Patriot Lithium grows 95% on stunning debut, because… lithium. Obviously. Welp… that’s it for the final day of the week, and as te...

Highlights The ASX 200 benchmark index closed in the green today (December 9), gaining 36.10 points or 0.50% to end at 7,211.60 points. Over the last five days, the index has lost 1.23% and 2.34% over the last 52 weeks. Materials was...

CardieX (CDX) subsidiary ATCOR pens a new clinical trial services agreement for its XCEL devices and data management servicesATCOR’s products and services will be used in a clinical trial to determine arterial health outcomes for the assess...

ASX 200 down 0.41% on lower than normal volume  Small cap index falls 1.17% and 7 out 11 sectors finish lower RBA raises the cash rate by 25 basis points to 3%   The ASX200 was down 0.41% today. The ASX Emerging Companies (XEC) index was...

Well… that was Tuesday, everyone. We trust you’ve had a great day, and hope that the whims of the Market Gods mean that you’ve managed to dodge the let-downs and can still put your hand in your pocket to pay for a pizza when you get home. B...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Medtech CardieX has successfully ruled off a $4.33 million placement to fast track the commercialisation of the company’s dual blood pressure and arterial health monitoring technology, the CONNEQT Pulse. CardieX (ASX:CDX) has been strongly...

Health technology company CardieX (CDX) raises $4.33 million under its placement and launches a $1 million share purchase plan (SPP) The placement funds were raised through the issue of more than 14.43 million shares to directors, domestic...

The ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, with Tech leading the losers CBA says the unemployment rate is at its lowest in 48 years   Despite creeping up earlier in the week the ASX 20...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Literally every sector had a red month, but mining was the worst PayGroup gets surprise $120m takeover offer from US unicorn Deel Tempest Minerals signed JV to explore near the Karara Magnetite Iron mine June was a month of global econom...

CardieX (CDX) and its manufacturing partner, Andon, submit its blood pressure and arterial health monitor, CONNEQT Pulse, to the US Food and Drug Administration (FDA) Subject to FDA clearance, Pulse will be the first arterial health monito...

Orthocell jumps 35% after signing global license deal Imricor in with Siemens deal on 3D imaging system CardieX submits “Pulse” application with US FDA  Orthocell (ASX:OCC) jumped by over 35% this morning after signing a 25-year exclusive...

CardieX is a step closer to launching its world first CONNEQT Pulse dual blood pressure monitor, after filing a clearance submission with the US FDA Australian medical technology companyn CardieX Limited (ASX:CDX), has, together with its ma...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The US FDA has classified CardieX’s (CDX) CONNEQT Companion app as a Medical Device Data System (MDDS) The app will work in line with the CONNEQT Pulse device, which is a dual blood pressure management system CardieX says the classificatio...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Supply chains are constrained globally as the world gets back on its feet This comes as inflation takes off, adding upward price pressures caused by scarcity of supply These conditions translate to major headwinds for contractors who agree...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

CardieX unveils the TicWatch GTH Pro made by global consumer electronics company Mobvoi using technology made by CDX’s subsidiary, ATCOR. The smartwatch uses ATCOR’s ‘Arty’ technology to measure central arterial waveforms and detect the ha...

The ASX200 has come to a jerky halt, closing more than 50 points or 0.7% higher. The market is down 5.6% over the last 52 weeks. The ASX Emerging Companies (XEC) index ended 0.6% better. The Four Horsemen of the Apocalypse are abroad on Mon...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

So basically, this is how I read it. Because of two really screwball takeover ideas involving the A2 Milk Co and AGL Energy —  two of the more screwball companies floating about on the benchmark index — the S&P/ASX200 is higher on Monda...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

CardieX’s (CDX) subsidiary teams up with Andiwn Scientific for a global clinical trial of ATCOR XCEL device and data management services ATCOR has entered a new global clinical trial services agreement with Andwin Scientific to support Syn...

Local stocks end up posting a solid session on Monday, following some steady gains on Wall Street on Friday night. Things looked shaky early, but the ASX 200 steadied in afternoon trade to finish around 0.5% higher. ASX 200 tech stocks rose...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Analysts have labelled CardieX and its blood pressure tech a Christmas buy for growth in 2022. A leading independent analyst has put a conservative buy price target – triple the current price – on Aussie medtech CardieX Limited (ASX:CDX) s...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

CardieX and Mobvoi are poised to release a world-first consumer smartwatch with proprietary heart-health features leveraging CardieX subsidiary ATCOR’s FDA-cleared SphygmoCor® technology. Australian medtech CardieX Limited (ASX:CDX) has an...

CardieX takes a step closer to world first wearable after signing manufacturing deal with Shenzhen-based Fenda Technology Co. Australian medtech, CardieX Limited (ASX:CDX) has entered into a manufacturing & development partnership with...

While Apple fanatics eagerly await its next smartwatch with a heart monitor, there are a couple of ASX stocks that are competing with them — and one might even be ahead. Apple’s (NDQ:AAPL) smartwatches first hit the market in 2015 and have...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

There’s no doubt there’s a building boom right now in the US, with the Biden administration investing big bucks to create and preserve more than 2 million sustainable homes as part of its Build Back Better Agenda. And while there’s volatili...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead’s Q-Wrapz video series features one-on-one interviews showcasing the latest quarterly results of emerging ASX companies. In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Craig Cooper,...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...